Page last updated: 2024-11-02

palmidrol and Cacosmia

palmidrol has been researched along with Cacosmia in 4 studies

palmidrol: a cannabinoid receptor-inactive eCB-related molecule used as prophylactic in helping to prevent respiratory viral infection
palmitoyl ethanolamide : An N-(long-chain-acyl)ethanolamine that is the ethanolamide of palmitic (hexadecanoic) acid.

Research Excerpts

ExcerptRelevanceReference
"Patients with long COVID olfactory dysfunction were allocated to different groups based on the presence ("previously treated") or absence ("naïve") of prior exposure to olfactory training."3.11Effect of Ultra-Micronized Palmitoylethanolamide and Luteolin on Olfaction and Memory in Patients with Long COVID: Results of a Longitudinal Study. ( Brenner, MJ; Camaioni, A; Carriere, G; De Luca, P; Di Stadio, A; Marra, P; Montemurro, N; Pucci, R; Ricciardi, L; Salzano, G, 2022)

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's4 (100.00)2.80

Authors

AuthorsStudies
Di Stadio, A4
D'Ascanio, L2
Vaira, LA1
Cantone, E1
De Luca, P3
Cingolani, C2
Motta, G1
De Riu, G1
Vitelli, F2
Spriano, G1
De Vincentiis, M1
Camaioni, A3
La Mantia, I2
Ferreli, F2
Brenner, MJ4
Marra, P1
Salzano, G1
Carriere, G1
Ricciardi, L1
Pucci, R1
Montemurro, N1
Gallina, S1
Cocuzza, S1
Ingrassia, A1
Oliva, S1
Sireci, F1
Mercante, G1
Gaino, F1
Pace, GM1
Maranzano, M1

Trials

4 trials available for palmidrol and Cacosmia

ArticleYear
Ultramicronized Palmitoylethanolamide and Luteolin Supplement Combined with Olfactory Training to Treat Post-COVID-19 Olfactory Impairment: A Multi-Center Double-Blinded Randomized Placebo- Controlled Clinical Trial.
    Current neuropharmacology, 2022, Volume: 20, Issue:10

    Topics: Amides; COVID-19; Dietary Supplements; Ethanolamines; Humans; Luteolin; Olfaction Disorders; Palmiti

2022
Effect of Ultra-Micronized Palmitoylethanolamide and Luteolin on Olfaction and Memory in Patients with Long COVID: Results of a Longitudinal Study.
    Cells, 2022, 08-17, Volume: 11, Issue:16

    Topics: Amides; COVID-19; COVID-19 Drug Treatment; Ethanolamines; Female; Humans; Longitudinal Studies; Lute

2022
Treatment of COVID-19 olfactory dysfunction with olfactory training, palmitoylethanolamide with luteolin, or combined therapy: a blinded controlled multicenter randomized trial.
    European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2023, Volume: 280, Issue:11

    Topics: COVID-19; Humans; Luteolin; Olfaction Disorders; Olfactory Training; Smell

2023
Randomized clinical trial "olfactory dysfunction after COVID-19: olfactory rehabilitation therapy vs. intervention treatment with Palmitoylethanolamide and Luteolin": preliminary results.
    European review for medical and pharmacological sciences, 2021, Volume: 25, Issue:11

    Topics: Adult; Amides; Anti-Inflammatory Agents, Non-Steroidal; Antiviral Agents; COVID-19; COVID-19 Drug Tr

2021